Inozyme Pharma, Inc.
INZY
$1.26
-$0.23-15.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -43.35% | -41.55% | -30.42% | -14.10% | -6.13% |
| Total Depreciation and Amortization | -10.92% | -5.84% | -1.99% | 4.53% | 11.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.92% | -37.59% | -73.13% | -81.42% | -58.08% |
| Change in Net Operating Assets | 252.95% | 151.37% | 285.48% | -163.92% | -253.18% |
| Cash from Operations | -30.04% | -36.97% | -37.46% | -26.17% | -22.36% |
| Capital Expenditure | 79.19% | 37.24% | 62.01% | 72.71% | 27.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 225.70% | 203.47% | -214.79% | -317.16% | -968.46% |
| Cash from Investing | 224.89% | 202.57% | -200.99% | -301.56% | -892.89% |
| Total Debt Issued | -- | -54.55% | -60.38% | -16.84% | 887.65% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -86.74% | -87.02% | 328.87% | 25.42% | 25.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.95% | -79.15% | 72.77% | 14.45% | 73.06% |
| Foreign Exchange rate Adjustments | 122.22% | 243.43% | -161.90% | -400.00% | 28.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -928.65% | -894.87% | -17.39% | -266.55% | -83.02% |